We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Breakthrough Diagnostic Technology Enables Quantitative Five-Minute Tests

By LabMedica International staff writers
Posted on 09 Nov 2022
Print article
Image: The ProciseDx Instrument can run quantitative 5-minute tests (Photo courtesy of ProciseDx)
Image: The ProciseDx Instrument can run quantitative 5-minute tests (Photo courtesy of ProciseDx)

Fast and accurate diagnostic results have become familiar. But many medical decisions rely on a quantitative diagnostic result. The doctor needs a number, not just a positive or negative. Now, a breakthrough diagnostic technology enables quantitative five-minute tests that deliver easy, immediate and accurate results to expedite medical treatment.

ProciseDx Inc. (San Diego, CA, USA) has received FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives quantitative determination of CRP levels in patient serum in less than five minutes. The company expects FDA clearances of additional tests in 2023. ProciseDx has a menu of five-minute gastroenterology and Therapeutic Drug Monitoring (TDM) tests available in Europe.

ProciseDx has obtained CE Marks and launched four gastroenterology (GI) tests in Europe. Already 30 ProciseDx instruments are installed and supporting patient care, with a further 50 sites working towards implementation. For the US market, ProciseDx has submitted De Novo applications to the FDA for two TDM tests. Procise IFX measures infliximab (Remicade and biosimilars) and Procise ADL measures adalimumab (Humira and biosimilars). ProciseDx expects to commercialize its GI and TDM menu in the US in 2023, launching with Procise IFX, Procise ADL and Procise CRP.

"Accurate quantitative diagnostic results have typically required big lab instruments and taken several hours or days," said Larry Mimms, President & Chief Scientific Officer. "The ProciseDx platform can change that, with a simple workflow producing a reliable quantitative measurement in five minutes or less."

"Remicade and Humira are hugely important drugs for patients with IBD (Inflammatory Bowel Disease) and ProciseDx monitoring of these drugs is improving care in Europe," said Peter Westlake, ProciseDx CEO. "ProciseDx technology is a real step forward, because it can deliver reliable quantitative results from a drop of blood in five minutes or less. We're preparing to bring these additional ProciseDx five-minute tests to doctors and patients in the US."

Related Links:
ProciseDx Inc.

Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
Blood Transfusion Safety Test
ABTest Card
Automatic IFA Processor
Fecal Occult Blood Test
iFOB Assay

Print article


Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more


view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more


view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more


view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.